In 2001, Dr. Carmeliet documented that low VEGF levels in mice and in humans cause motorneuron degeneration, similar to patients suffering the incurable disease amyotrophic lateral sclerosis (ALS). These studies not only provide evidence for a role of VEGF in neurodegeneration, but also opened therapeutic opportunities, which have resulted in clinical tests of VEGF delivery for ALS patients. The Carmeliet lab is currently studying how endothelial cells change their metabolism during vascular branching and exploring the therapeutic potential of targeting endothelial metabolism for anti-angiogenic strategies.
Dr. Carmeliet published over 480 research articles and reviews, his achievements have been recognized by several International Honors and Awards.
Back to top
DCP Home |
Contact DCP |
Viewing Files |
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®